Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.60 |
| ▸ | ARG2 | P78540 | 1/20 | 0.60 |
| ▸ | NOS2 | P35228 | 4/20 | 0.58 |
| ▸ | NOS1 | P29475 | 2/20 | 0.58 |
| ▸ | NOS3 | P29474 | 1/20 | 0.58 |
| ▸ | BHMT | Q93088 | 4/20 | 0.44 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1157633 | 1.00 | ARG1 (0.60) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL8084363 | 1.00 | ARG1 (0.60) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL28472089 | 0.98 | ARG1 (0.58) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL1157602 | 0.88 | NOS2 (0.60) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL14375190 | 0.88 | NOS2 (0.60) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL1157599 | 0.88 | NOS2 (0.60) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL17361239 | 0.86 | ARG1 (0.69) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL17361240 | 0.86 | ARG1 (0.69) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL2425454 | 0.86 | NOS2 (0.58) | ARG1ARG2NOS2NOS1NOS3 | |
| SCHEMBL2425458 | 0.86 | NOS2 (0.58) | ARG1ARG2NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220233501-A1 | THERAPEUTIC COMBINATIONS | SUPERSALUS INC (US) | 2022-07-28 | — | — | US | claimed |
| WO-2020167748-A1 | THERAPEUTIC COMBINATIONS | SUPERSALUS, INC. (US) | 2020-08-20 | — | — | WO | claimed |
| US-20200253926-A1 | THERAPEUTIC COMBINATIONS | SUPERSALUS, INC. | 2020-08-13 | — | — | US | claimed |
| US-20200116730-A1 | METHOD AND SYSTEM FOR THE NON-DESTRUCTIVE IN OVO DETERMINATION OF FOWL GENDER | IN OVO B.V. (NL) | 2020-04-16 | — | — | US | claimed |
| EP-3465222-A2 | METHOD AND SYSTEM FOR THE NON-DESTRUCTIVE IN OVO DETERMINATION OF FOWL GENDER | In Ovo B.V. (NL) | 2019-04-10 | — | — | EP | claimed |
| CN-109477840-A | For non-destructively determining the method and system of Fowl Sex in ovum | 因欧沃私人有限责任公司 | 2019-03-15 | — | — | CN | claimed |
| WO-2017204636-A2 | METHOD AND SYSTEM FOR THE NON-DESTRUCTIVE IN OVO DETERMINATION OF FOWL GENDER | IN OVO B.V. (NL) | 2017-11-30 | — | — | WO | claimed |
| EP-2629769-B1 | CYSTEINE AND AGEING-ASSOCIATED ANOREXIA | NESTEC SA (CH) | 2017-10-04 | — | — | EP | claimed |
| US-9233090-B2 | Cysteine and food intake | NESTEC S.A. (CH) | 2016-01-12 | — | — | US | claimed |
| US-20130225486-A1 | CYSTEINE AND FOOD INTAKE | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2013-08-29 | — | — | US | claimed |
| EP-2629769-A1 | CYSTEINE AND FOOD INTAKE | Nestec S.A. (CH) | 2013-08-28 | — | — | EP | claimed |
| WO-2012052463-A1 | CYSTEINE AND FOOD INTAKE | NESTEC S.A. (CH) | 2012-04-26 | — | — | WO | claimed |
| EP-2444083-A1 | Cysteine and food intake | Nestec S.A. (CH) | 2012-04-25 | — | — | EP | claimed |
| WO-2006039285-A2 | COMPOSITIONS AND METHODS FOR INDUCING ADIPOSE TISSUE CELL DEATH | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2006-04-13 | — | — | WO | claimed |
| EP-0972454-B1 | Use of sulfur containing organic compounds as agents for bathochromically shifting the UV/vis-absorption bands of carotenoids | BASF AG (DE) | 2003-10-15 | — | — | EP | claimed |
| US-6271396-B1 | Use of organosulfur compounds for effecting a bathocromic shift in the UV/vis absorption bands of carotenoids | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-07 | — | — | US | claimed |
| JP-62000423-A | — | — | None | — | — | JP | disclosed |
| US-20260124167-A1 | SIRTUIN ACTIVATOR OR EXPRESSION ENHANCER, NAD+ INCREASING AGENT, AND SENESCENT CELL INHIBITOR | WAKUNAGA PHARMA CO LTD (JP) | 2026-05-07 | — | — | US | disclosed |
| CN-1249304-A | Implementation of red shift using organic sulfur compound in ultraviolet/visible light absorption band of carotenoid | BASF AG (DE) | 2000-04-05 | — | — | CN | disclosed |
| JP-S62423-A | REMEDY FOR HEPATOPATHY | WAKUNAGA PHARMACEUT CO LTD | 1987-01-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124167-A1 | SIRTUIN ACTIVATOR OR EXPRESSION ENHANCER, NAD+ INCREASING AGENT, AND SENESCENT CELL INHIBITOR | SIRT1, SIRT3, SIRT2 | ARG1 322/4885ARG2 89/4885NOS2 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.